NR3C1

1 clinical trials · Condition

Record	Firm	Date
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma (NCT07579208)	M.D. Anderson Cancer Center	2026-10-24

Every clearance here is in the API, with alerts when new ones post.